Price Chart

DATE TIME TYPE PERIOD REPORTED
EPS
ESTIMATED
EPS
SURPRISE
08/05/2022* -- Results Q2 2022 -- -0.36 --
08/05/2022* 08:00 EST Earnings Call Q2 2022 -- -- --
05/16/2022 -- Results Q1 2022 -0.40 -0.29 -39.01%
05/16/2022 08:00 EST Earnings Call Q1 2022 -- -- --
03/29/2022 -- Results Q4 2021 -0.35 -0.35 -1.90%
03/29/2022 08:00 EST Earnings Call Q4 2021 -- -- --
11/15/2021 -- Results Q3 2021 -0.37 -0.39 5.48%
11/15/2021 08:30 EST Earnings Call Q3 2021 -- -- --
*Estimated Date/Time

Earnings

Next Report Date 08/05/2022 (est.)
EPS Estimate Upgrade
Last Actual EPS Upgrade

Loading chart...
Last Report Date 05/16/2022
Beat/Miss Upgrade
Return Since -51.26%
Last FQE 03/31/2022
Next FQE 06/30/2022

Profile

Edit
Kala Pharmaceuticals Inc is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye. The company's two marketed products are EYSUVIS and INVELTYS.
URL https://www.kalarx.com
Investor Relations URL https://investors.kalarx.com/
HQ State/Province Massachusetts
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Equity Style Small Cap/Value
Next Earnings Release Aug. 05, 2022 (est.)
Last Earnings Release May. 16, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Dividends

Dividend Per Share (TTM) --
2017
2018
2019
2020
2021
No data available
 
6.00%
4.00%
2.00%
 
Yield to Market 0.00
Yield to Sector 0.00
Yield to Industry 0.00
Last Dividend Amt. --
Dividend Frequency --
Last Ex-Dividend Date --
Yield (TTM) 0.00%
Forward Yield --
Payout Ratio 0.00%
Cash Payout Ratio 0.00%
Consistent Payer (5Y) No
Consistent Growth (5Y) No

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Total Returns Comparison

Edit comparables

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2015
2016
2017
2018
2019
2020
2021
YTD
--
--
--
-73.55%
-24.54%
83.74%
-82.15%
-70.13%
1.38%
11.96%
21.83%
-4.38%
31.49%
18.40%
28.71%
-17.31%
56.85%
-66.70%
-33.39%
-96.85%
-9.48%
-24.44%
-28.93%
-28.80%
-17.60%
-84.17%
-37.01%
-47.39%
21.28%
-58.42%
-24.05%
-76.54%
122.5%
-84.97%
214.2%
-25.12%
6.35%
26.35%
15.04%
-41.91%
-72.92%
-79.23%
39.88%
-42.16%
-13.69%
-7.34%
-85.52%
65.21%
As of June 24, 2022.

Profile

Edit
Kala Pharmaceuticals Inc is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye. The company's two marketed products are EYSUVIS and INVELTYS.
URL https://www.kalarx.com
Investor Relations URL https://investors.kalarx.com/
HQ State/Province Massachusetts
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Equity Style Small Cap/Value
Next Earnings Release Aug. 05, 2022 (est.)
Last Earnings Release May. 16, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Top Fund Holders

No data available
Symbol Dollars Invested % Weight
     
     
     
     
     
     
     
     
     
     

Top Portfolio Holders

0 of 0

Other Resources

Whale Wisdom 13F Filings
Seeking Alpha Call Transcripts
Morningstar Insider Trading
Nasdaq Institutional Ownership
Nasdaq Option Chain
SEC SEC Filings
Twitter KALA Tweets